First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
RSV
first-in-human study
viral vector vaccine
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 05 2020
06 05 2020
Historique:
received:
31
12
2018
accepted:
19
07
2019
pubmed:
25
7
2019
medline:
7
1
2021
entrez:
25
7
2019
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine against RSV (ChAd155-RSV) using the viral vector chimpanzee-adenovirus-155, encoding RSV fusion (F), nucleocapsid, and transcription antitermination proteins. Healthy 18-45-year-old adults received ChAd155-RSV, a placebo, or an active control (Bexsero) at Days (D) 0 and 30. An escalation from a low dose (5 × 109 viral particles) to a high dose (5 × 1010 viral particles) occurred after the first 16 participants. Endpoints were solicited/unsolicited and serious adverse events (SAEs), biochemical/hematological parameters, cell-mediated immunogenicity by enzyme-linked immunospot, functional neutralizing antibodies, anti RSV-F immunoglobin (Ig) G, and ChAd155 neutralizing antibodies. There were 7 participants who received the ChAd155-RSV low dose, 31 who received the ChAd155-RSV high dose, 19 who received the placebo, and 15 who received the active control. No dose-related toxicity or attributable SAEs at the 1-year follow-up were observed. The RSV-A neutralizing antibodies geometric mean titer ratios (post/pre-immunization) following a high dose were 2.6 (D30) and 2.3 (D60). The ratio of the fold-rise (D0 to D30) in anti-F IgG over the fold-rise in RSV-A-neutralizing antibodies was 1.01. At D7 after the high dose of the study vaccine, the median frequencies of circulating B-cells secreting anti-F antibodies were 133.3/106 (IgG) and 16.7/106 (IgA) in peripheral blood mononuclear cells (PBMCs). The median frequency of RSV-F-specific interferon γ-secreting T-cells after a ChAd155-RSV high dose was 108.3/106 PBMCs at D30, with no increase after the second dose. In adults previously naturally exposed to RSV, ChAd155-RSV generated increases in specific humoral and cellular immune responses without raising significant safety concerns. NCT02491463.
Sections du résumé
BACKGROUND
Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine against RSV (ChAd155-RSV) using the viral vector chimpanzee-adenovirus-155, encoding RSV fusion (F), nucleocapsid, and transcription antitermination proteins.
METHODS
Healthy 18-45-year-old adults received ChAd155-RSV, a placebo, or an active control (Bexsero) at Days (D) 0 and 30. An escalation from a low dose (5 × 109 viral particles) to a high dose (5 × 1010 viral particles) occurred after the first 16 participants. Endpoints were solicited/unsolicited and serious adverse events (SAEs), biochemical/hematological parameters, cell-mediated immunogenicity by enzyme-linked immunospot, functional neutralizing antibodies, anti RSV-F immunoglobin (Ig) G, and ChAd155 neutralizing antibodies.
RESULTS
There were 7 participants who received the ChAd155-RSV low dose, 31 who received the ChAd155-RSV high dose, 19 who received the placebo, and 15 who received the active control. No dose-related toxicity or attributable SAEs at the 1-year follow-up were observed. The RSV-A neutralizing antibodies geometric mean titer ratios (post/pre-immunization) following a high dose were 2.6 (D30) and 2.3 (D60). The ratio of the fold-rise (D0 to D30) in anti-F IgG over the fold-rise in RSV-A-neutralizing antibodies was 1.01. At D7 after the high dose of the study vaccine, the median frequencies of circulating B-cells secreting anti-F antibodies were 133.3/106 (IgG) and 16.7/106 (IgA) in peripheral blood mononuclear cells (PBMCs). The median frequency of RSV-F-specific interferon γ-secreting T-cells after a ChAd155-RSV high dose was 108.3/106 PBMCs at D30, with no increase after the second dose.
CONCLUSIONS
In adults previously naturally exposed to RSV, ChAd155-RSV generated increases in specific humoral and cellular immune responses without raising significant safety concerns.
CLINICAL TRIALS REGISTRATION
NCT02491463.
Identifiants
pubmed: 31340042
pii: 5537685
doi: 10.1093/cid/ciz653
pmc: PMC7201425
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Respiratory Syncytial Virus Vaccines
0
Viral Proteins
0
Banques de données
ClinicalTrials.gov
['NCT02491463']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2073-2081Subventions
Organisme : Wellcome Trust
ID : 109965/Z/15/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409569
J Immunol. 2008 Nov 15;181(10):6692-6
pubmed: 18981084
Sci Transl Med. 2015 Aug 12;7(300):300ra126
pubmed: 26268313
J Virol. 2014 Mar;88(6):3135-43
pubmed: 24371055
Int J Mol Sci. 2017 Aug 11;18(8):
pubmed: 28800119
Vaccine. 2016 Sep 22;34(41):4875-4883
pubmed: 27576071
PLoS One. 2017 May 22;12(5):e0177803
pubmed: 28531224
Clin Microbiol Rev. 2017 Apr;30(2):481-502
pubmed: 28179378
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
Epidemiol Infect. 2016 Jun;144(8):1622-33
pubmed: 26732801
Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95
pubmed: 26677198
Sci Transl Med. 2014 Nov 5;6(261):261ra153
pubmed: 25378645
Methods Mol Biol. 2017;1581:3-13
pubmed: 28374240
Curr Opin Virol. 2017 Apr;23:107-112
pubmed: 28525878
J Infect Dis. 2017 Dec 12;216(11):1398-1406
pubmed: 29029312
J Exp Med. 2002 Sep 16;196(6):859-65
pubmed: 12235218
Hum Vaccin Immunother. 2017 Dec 2;13(12):2814-2823
pubmed: 28604155
Vaccine. 2016 Jun 3;34(26):2870-2875
pubmed: 27105562
Expert Rev Vaccines. 2013 Apr;12(4):379-93
pubmed: 23560919
Expert Rev Vaccines. 2007 Apr;6(2):255-66
pubmed: 17408374
J Virol. 2017 Jul 12;91(15):
pubmed: 28539438
Curr Opin Immunol. 2016 Aug;41:47-54
pubmed: 27286566
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
AIDS. 2016 Oct 23;30(16):2405-2414
pubmed: 27525550
Infect Dis Ther. 2017 Jun;6(2):173-197
pubmed: 28357706